Daily Archives: September 1, 2017

Risk for Hepatocellular Carcinoma After Hepatitis C Virus Antiviral Therapy With Direct-acting Antivirals: Case Closed?

Posted on September 1, 2017 by Gastroenterology Journal

The development of direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection was well-received by patients and physicians, as viral clearance is associated with improved liver-related and overall survivals.1,2 Despite this … Continue reading →

Posted in News | Comments Off on Risk for Hepatocellular Carcinoma After Hepatitis C Virus Antiviral Therapy With Direct-acting Antivirals: Case Closed?

Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease

Posted on September 1, 2017 by Gastroenterology Journal

Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease is a comprehensive review of the use of anti-tumor necrosis factor (TNF) therapy in patients with inflammatory bowel disease (IBD). The book includes a preface and 35 chapters, which can … Continue reading →

Posted in News | Comments Off on Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease